Invitae - News & Events - Press releases

December 20, 2022 Invitae Completes Selected Assets Sale of its Next Generation Sequencing (NGS) research assays to Integrated DNA Technologies, Inc.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it has completed a transaction with Integrated DNA Technologies, Inc. (IDT), which includes the sale of Next Generation Sequencing (NGS) research assays under the trademarked name Archer ® , also known as the Research Use Only (RUO) kitted solutions. The transaction also includes certain licensed rights to Invitae's Anchored Multiplex PCR (AMP™) technology. The transaction value includes total cash consideration of approximately $48 million, subject to certain adjustments. As part of the transaction, Invitae also entered into a supply agreement with IDT to support Invitae's PCM services. This divestiture is part of Invitae's portfolio optimization efforts and renewed strategic focus to achieve profitable growth in its core genetic testing business, fueling the pursuit of the significant market opportunities of its precision oncology LDT services. This transaction is expected to add to

December 19, 2022 Invitae Executive Appointed to National Health Information Technology Advisory Committee

Invitae (NYSE: NVTA), a leading medical genetics company, announced the appointment by the U.S. Government Accountability Office (GAO) of Deven McGraw, lead of data stewardship and data sharing at Invitae, to the National Health Information Technology Advisory Committee (HITAC). Established as part of the 21st Century Cures Act in 2016, HITAC provides recommendations to the National Coordinator for Health Information Technology on policies, standards, implementation specifications, and certification criteria relating to the implementation of a health information technology infrastructure that advances the electronic access, exchange, and use of health information. "I am honored to be appointed to HITAC to help shape the nation's health information policy, particularly as it relates to increasing access to important patient health data in a way that is ethical and transparent," said McGraw. "Through my participation on HITAC's 2022 Adopted Standards Task Force subcommittee, I've

December 7, 2022 Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the release of its Data Use Transparency and Impact Report, which details how the company has used de-identified patient data to advance precision medicine. While many companies collect patient data, they do not disclose how this data is being used. Invitae is leading the industry by publishing this first-of-its-kind report on how it used de-identified patient data for secondary data research in 2021. Unlike most companies, Invitae offers patients a choice on whether or not to allow access to their de-identified data for research. As a company grounded in the principles that patients own and control their data and that data is more valuable when shared, this report demonstrates how Invitae delivers on those principles in a way that honors the intent of patients with the ultimate goal of advancing the science of genomics and precision medicine. "For precision medicine to advance and real-world evidence to matter,

December 1, 2022 Invitae Launches Rare Patient Network for Pediatric Patients With Rare Neurodevelopmental Diseases

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of the Rare Patient Network expanding Invitae's Ciitizen platform to all patients with pediatric epilepsy and/or developmental delay with plans to include other conditions in the coming months. By engaging with a broader community, Invitae, a leader in the rare pediatric neurodevelopmental field, aims to create value for significantly more patients with rare diseases. Identifying and recruiting patients with rare diseases into clinical studies is difficult, making it challenging to understand the etiology, disease course, differences among subpopulations and the impact of novel treatments. The Rare Patient Network is a new approach to solving these challenges by directly engaging with the broader community of patients with rare neurodevelopmental conditions. "The Rare Patient Network is a proactive way to empower patients," said Terry Jo Bitchell, PhD., executive director of COMBINEDBrain. "Even

November 10, 2022 Invitae Showcases Advances in Medical Genomics at the National Society of Genetic Counselors (NSGC) 41st Annual Conference

Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are presenting research next week at the National Society of Genetic Counselors (NSGC) 41st Annual Conference in Nashville enabling the progress of the science and practice of genetics in patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award, which recognizes excellence in the field of genetic counseling. The company's research presentations, which include a pre-conference symposium, sponsored session and poster presentations, add to both the science and practice of the fast-growing field of medical genetics. Among the company's poster presentations is a retrospective case-control study aimed to assess the cancer risk for individuals who have a monoallelic MUTYH pathogenic/likely pathogenic variant. In addition, Invitae will present a study highlighting how RNA sequencing can help classify variants predicted to alter RNA splicing, as

November 8, 2022 Invitae Reports Third Quarter 2022 Financial Results

— Continued to execute against realignment plan and portfolio optimization initiatives — — Reported revenue of $133.5 million, a 16.7% YoY increase — — Cash, cash equivalents, restricted cash and marketable securities of $596 million as of 9/30 — — On track to achieve planned cash burn reduction of approximately $326 million, to be fully realized by 2023 — — 2022 cash burn guidance lowered; maintained other financial targets — — Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Tim e — Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2022. "In the third quarter, we continued to deliver positive results as the organizational realignment and expense controls we put in place resulted in another quarter of improvements in our non-GAAP gross margin and operating expense, as well as our cash burn. There are also early signs demonstrating that the steps

October 31, 2022 Invitae study shows therapy informed by genetic testing reduces seizures in some patients with epilepsy

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the findings of a study that documents the actions clinicians take upon receiving a positive diagnostic genetic testing result for patients with epilepsy. The findings, in JAMA Neurology , demonstrate that a positive genetic diagnosis leads to clinical management changes in approximately half of patients and that changes implemented by clinicians based on genetic testing improve health outcomes in as many as three quarters of patients. When a change in management is made based on the results of a positive genetic test result, outcomes for patients with epilepsy generally improve, including reduction, and even complete elimination of seizures. "Precision medicine is increasingly becoming an important reality in the clinical care of children and adults with epilepsy. The observations from this study, derived from clinical practices in multiple countries and clinical settings, underscore the urgency of adopting a

October 28, 2022 Invitae to Present Data at the American Society of Human Genetics Annual Meeting Furthering the Understanding of Variants of Uncertain Significance in Underrepresented Populations

Invitae (NYSE: NVTA), a leading medical genetics company, will present data from its genetic testing portfolio at the American Society of Human Genetics Annual Meeting taking place in Los Angeles, Calif., October 25-29, 2022. Researchers from Invitae will highlight the importance of monitoring and addressing variants of uncertain significance (VUS) when it comes to underrepresented populations and the implications about how broadening access and participation in genomics research is paramount to addressing health inequities. The company's research includes two platform presentations and one CoLab session co-presented with partner Illumina discussing the barriers and solutions to expanding access to genetic testing and research. Among the data being presented is a study sharing a deeper understanding of the variants of uncertain significance (VUS) reporting landscape and offering best practices for labs and clinicians to determine clearly defined actions that clinicians and patients

October 27, 2022 Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research

Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to use Invitae's Ciitizen natural history data in a retrospective and prospective study of patients diagnosed with cholangiocarcinoma, a rare bile duct cancer. This partnership will enable sharing of high-quality, patient-consented data from the patient community of the Cholangiocarcinoma Foundation (CCF), a leading patient advocacy group whose mission is to find a cure and improve the quality of life for those with cholangiocarcinoma. "CCF partnered with Invitae to use the Ciitizen data platform in its earliest days because we saw a need for our patient community to gain control of their own medical records and drive research with their own health data," said Stacie Lindsey, CEO, Cholangiocarcinoma Foundation. "This is a groundbreaking example of how patient-initiated research and the quality of data Invitae's Ciitizen platform produces from medical records

October 25, 2022 Invitae to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register at the link below: https://events.q4inc.com/attendee/944547022 Upon registering, each participant will be provided with call details and access codes. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA ) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of

September 27, 2022 Invitae Appointed to National Quality Forum Committee on Quality Standards for Healthcare

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the company has received a three-year appointment to a National Quality Forum (NQF) committee that provides input on recommendations for quality standards that impact how healthcare is delivered. Invitae is the first genetics testing company to join the Measure Applications Partnership (MAP) Clinician workgroup committee, representing a critical step in making genetics the standard of care in mainstream medicine and potentially improving healthcare for billions. The MAP Clinician workgroup is a multi-stakeholder partnership with organizations such as health plans and provider organizations tasked with providing recommendations to the U.S. Department of Health and Human Services on the selection and removal of performance measures for federal public reporting, performance-based payment and other health programs. "The selection of Invitae to the MAP Clinician workgroup indicates the National Quality Forum is

September 22, 2022 Clinical Practice Guidelines Recommend Genetic Testing of All Patients with Breast Cancer

Invitae (NYSE: NVTA), a leading medical genetics company, released a new study in JAMA Network Open , underscoring the clinical utility of the American Society of Breast Surgeons (ASBrS) guidelines recommending universal genetic testing for patients with breast cancer, and showing universal testing improves patient outcomes. Building on a previous study reported in the Journal of Clinical Oncology , the current study is the first clinical outcomes study of a cohort of unselected patients with breast cancer who underwent universal germline genetic testing. Our data show that genetic information aids patients and their physicians in implementing effective precision treatments and personalized management for their cancer. The data confirm the clinical utility of universal germline testing for all patients regardless of cancer type, age, stage or family history as cited in landmark studies published in JAMA Oncology and Clinical Gastroenterology and Hepatology by Invitae and Mayo Clinic .

September 20, 2022 Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing

Invitae (NYSE: NVTA) and Praxis Precision Medicines , Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae's Ciitizen platform were utilized as natural history data to support the submission of Praxis' Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy (DEE). Praxis announced earlier this month that the U.S. Food and Drug Administration (FDA) cleared the IND application for the initial dose cohort for the PRAX-222 EMBRAVE clinical study. For many well-established diseases, natural history studies and other rich data sets are available to support regulatory interactions and IND applications. For many rare diseases, including certain severe genetic pediatric epilepsies such as SCN2A-DEE, natural history studies are not yet available to document the high disease burden and significant unmet medical need. In addition, the usual method of collecting

September 15, 2022 Leading Clinical Experts Across the U.S. Unite to Support Universal Genetic Testing for all Patients with Cancer

Invitae (NYSE: NVTA), a leading medical genetics company, joined other clinical experts in releasing a new commentary in Journal of Clinical Oncology Precision Oncology , underscoring the importance of universal germline testing for all patients with cancer (solid tumors). The paper reports a meta-analysis of multiple clinical publications supporting universal testing, independent of age, stage, family history or type of cancer. It reports that for cancer types such as pancreatic and ovarian where universal genetic testing is already recommended, 13% and 20% of patients (respectively) have identifiable actionable heritable gene mutations ,2 . In comparison, the actionable inherited gene mutation rate for patients with other cancer types is similar: breast 11%, endometrial 13%, prostate 14%, kidney 13%, bladder 14%, testicular 13%, colorectal 13%, liver 14%, and stomach 14%. Furthermore, it reports that between 5-13% of patients with cancer with heritable gene mutations are missed by

September 12, 2022 Invitae and Simons Searchlight Partner to Accelerate Research through Data Sharing

Invitae (NYSE: NVTA), a leading medical genetics company, today announced a collaboration with Simons Searchlight, an international research program with a goal of accelerating research and improving lives for people with rare genetic neurodevelopmental disorders. This partnership will connect two sets of data – the longitudinal clinical data extracted from medical records through Invitae's Ciitizen, a patient-consented, digital natural history data platform and patient reported outcomes and biospecimens collected by Simons Searchlight. The partnership breaks down data silos and provides a rich and deep dataset that will help accelerate research for rare neurodevelopmental diseases. "We are excited about this collaboration that will allow researchers to get deep, rich longitudinal data on rare disease patients," said Farid Vij, president and general manager of data for Invitae. "This is intended to help improve treatment, with a goal of ultimately finding a cure for these rare

August 30, 2022 Invitae to Present at Upcoming Investor Conference

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following investor conference: Morgan Stanley 20th Annual Global Healthcare Conference – Fireside chat on Tuesday, September 13, 2022, at 8:00 a.m. Eastern Time in New York City, New York. A live audio webcast of the fireside chat may be accessed by visiting the investors section of the company website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com . Contact for Invitae:

August 9, 2022 Invitae Reports $136.6 Million in Revenue in Second Quarter of 2022

— Continued to execute towards operational excellence with portfolio optimization, broad cost controls and cash management — — Recently announced realignment plan is expected to extend the company's cash runway to the end of 2024; Maintain financial guidance — Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Tim e — Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2022. "In the second quarter, we are pleased with our progress towards achieving operational excellence, as demonstrated by the improvements in several key metrics focusing on non-GAAP gross margin, operating expense, and cash burn trajectory, both on a year-over-year and quarter-over-quarter basis. These numbers reflected positive results based on the initiatives that we have been implementing," said Ken Knight, president and chief executive officer of Invitae. "We recently announced our strategic

August 8, 2022 New NCCN Colorectal Cancer Guidelines Recommend Genetic Testing for All Diagnosed Patients

As a result of recent research revealing that a significant number of colorectal cancer patients with actionable variants are missed under previous genetic testing guidelines, the National Comprehensive Cancer Network (NCCN) announced new guidelines calling for testing to be available to all patients diagnosed with colorectal cancer. Specifically, NCCN recommended that germline multigene panel testing should be offered to all individuals with CRC age <50 and be considered for all others, particularly for, but not restricted to, those with evidence of mismatch repair in their tumor or suggestive family history. These new recommendations expand the current testing criteria, which limited testing to certain age groups and types of cancer. The new NCCN guidelines follow recent landmark studies published in JAMA Oncology and Clinical Gastroenterology and Hepatology by Invitae and Mayo Clinic supporting universal genetic testing for all cancer patients, regardless of cancer type, age,

August 2, 2022 Invitae to Announce Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2022 financial results on Tuesday, August 9, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register at the link below: https://events.q4inc.com/attendee/937240483 Upon registering, each participant will be provided with call details and access codes. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of

July 18, 2022 Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow and Realize Full Potential of Industry-Leading Genetics Testing Platform

— Exiting non-core businesses and geographies to prioritize higher-margin business initiatives — — Expects to deliver approximately $326 million in non-GAAP annualized cost savings in 2023 — — Provides preliminary revenue and gross margin ranges for the second quarter of 2022; amends full-year 2022 financial guidance — — Conference call and webcast today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time — Invitae (NYSE: NVTA), a leading medical genetics company, today announced a comprehensive plan to realize the full potential of its industry-leading genetics platform. The plan introduces a significant realignment of the company's operations in support of business lines and geographies that generate sustainable margins, provide the best return to fuel future investment and accelerate the company's path to positive cash flow. The plan further helps ensure Invitae remains at the forefront of innovation and advancements in genomics by allocating resources towards the company's core

July 18, 2022 Invitae Announces Leadership Transition

— COO Kenneth D. Knight named CEO succeeding Sean George; Dr. George to continue as member of Board of Directors — Invitae (NYSE: NVTA), a leading medical genetics company, today announced executive leadership and Board changes to help ensure the company realizes the full potential of its industry-leading genetics testing platform and delivers tangible and sustainable value for stockholders. Specifically, Kenneth D. Knight, who has served as Invitae's chief operating officer since 2020, is succeeding Sean George, Ph.D., as CEO and is joining the Board of Directors. Additionally, Randy Scott, Ph.D., Invitae's co-founder, former CEO from 2012 to 2017, and former executive chairman from 2017 to 2019, is returning to the company as chairman of the Board. Eric Aguiar, who has served as Invitae's independent chairman since 2019 and a member of the Board since 2010, is now serving as lead independent director. The changes are effective immediately. Dr. George, co-founder and CEO of Invitae

June 6, 2022 Aussies Must Rise To Genetics Challenge As New Analysis Reveals Raw Reality For Cancer Families

Leading patient organisation, Pink Hope, launches an advocacy collaboration to help Australian families get the answers they need sooner, as new analysis highlights the potential barriers and delays to genetic testing across the nation Families failed by red tape. A new analysis from Invitae, a leading medical genetics company, reveals that up to two-thirds of Australian breast cancer patients with high risk, hereditary gene variants (such as BRCA) would not qualify for genetic testing due to the nation’s eligibility criteria and would be unable to access what can be life-changing knowledge 1 . Consequences of delayed testing: For those who do receive a referral for genetic testing in NSW, they can face over a 12 month, or longer wait time3 – during which they and their family members could develop cancer, have their cancer progress, or not get access to personalised treatment that could increase survival. A new genetics advocacy collaboration launches today with the aim to educate

May 26, 2022 New Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access

Invitae (NYSE: NVTA), a leading medical genetics company, today announced eight studies to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from June 3-7, 2022. While the research covers a variety of cancer types, stages and patient demographics, all of the data underscore the importance of universal genetic testing to improve health outcomes for all cancer patients. Inherited genes impact risk for developing melanoma Melanoma—the most frequent cause of skin cancer-related deaths—is often perceived as a cancer caused by environmental factors. While sun exposure plays a role in most melanoma tumors, a new, first-of-its-kind study by Cleveland Clinic and Invitae found that genetics also play a critical role in the likelihood of developing melanoma. In fact, the study found that 15% of individuals with melanoma have inherited variants in a variety of genes associated with cancer predisposition syndromes, demonstrating multiple potential

May 19, 2022 Invitae Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the commercial availability of the expanded Invitae Pharmacogenomics (PGx) Panel which includes the specialized Invitae Pharmacogenomics Mental Health Panel and access to a clinical decision support tool (CDST). With this launch, Invitae now has one of the most comprehensive commercially available PGx panels in the industry. In addition to mental health medications, the panel aligns with PGx-specific guidelines and published evidence that affects hundreds of commonly used medications, including frequently prescribed medications for high-risk patients in primary care, cardiology, endocrinology, pain management and oncology. Nearly one in four patients has been prescribed medications for which they are predicted to have an atypical response due to their genetics. Given the compelling evidence that patient care can benefit from this information, PGx testing is poised to become the standard of care across all

May 3, 2022 Invitae Reports $123.7 Million in Revenue in First Quarter of 2022 and Extends Cash Runway

— Executing toward 2022 plan, generating near 20% revenue growth, with $885 million in ending cash* , an annualized burn reduction of greater than $100 million — — Broad OPEX controls and portfolio optimization to decrease spend, extend runway through 2023— — Company lays out path for continued industry-leading growth while achieving positive operating cash flow by end of 2025 — — Technology Day investor forum to be held week of July 11, roadmap for the creation of a new category in healthcare — — Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time — , a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2022. "The power of personal health information, enabled by a new breed of patient and clinician workflow tools, further combined with real world data, is an immense opportunity to shape the future of medicine. And while the proof points supporting our model of enabling a new era

April 20, 2022 Invitae to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register at the link below:
https://www.incommglobalevents.com/registration/q4inc/10749/invitae/#39s-first-quarter-2022-financial-results-conference-call/ Upon registering, each participant will be provided with call details and access codes. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose

April 4, 2022 Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the full commercial launch of its Neurodevelopmental Disorders (NDD) package to deliver a robust testing suite that can deliver actionable genetic insights to inform treatment plans for children with developmental disabilities. Invitae is the first to offer this particular suite of tests to clinicians and patients in an easily accessible format. The package includes chromosomal microarray analysis, analysis for fragile X-related disorders, and a next-generation-sequencing panel of 200+ genes in which variants are associated with neurodevelopmental disorders. The gene panel can detect sequence variants as well as full or partial gene deletions and duplications (i.e. intragenic copy number variants) that a chromosomal microarray analysis (CMA) alone may not detect. The comprehensive package provides reports for all three tests and can help provide clarity on the genetic etiology and root cause of these complex and

March 29, 2022 Introducing Invitae Digital Health--A Personalized Health Management Platform That Leverages Genomic Insights to Inform Health Decisions for Patients and Clinicians

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Invitae Digital Health—a connected digital health platform that informs health decisions through actionable genomic insights for patients and clinicians. With Invitae Digital Health, healthcare providers and health systems engage with a single, seamless platform that integrates important health data throughout each patient's lifetime. Rooted in genetic insights and scalable at the population level, it will enable a holistic approach to personalized health management for individuals throughout their health journey. Ushering in a new era of proactive healthcare With 19.3 million new cases of cancer worldwide in 2020, 420 million cases of cardiovascular disease 2 , 8 million children born with a serious genetic condition each year worldwide 3 , and 99% of people with genetic variation that can impact drug response 4 , the potential impact of genetics on mainstream healthcare is profound. A modular

March 17, 2022 Invitae Launches Full Access to its Liquid-Based Personalized Cancer Monitoring Platform to Help Detect Disease Earlier

Invitae (NYSE: NVTA), a leading medical genetics company, today announced full access to its Personalized Cancer Monitoring (PCM TM ) platform to help detect minimal or molecular residual disease (MRD) in patients with solid tumors. Invitae PCM uses a novel set of personalized assays based on a patient's tumor to detect circulating tumor DNA (ctDNA) in blood, offering the ability to perform risk stratification, response assessment to treatment and detection of cancer recurrence, based on recent studies. "Relapse risk stratification is a clinical need for many patients undergoing treatment for solid tumors and is best served by up-to-date molecular tools to complement and improve upon the standard of care methods for recurrence detection," said Robert Nussbaum, M.D., chief medical officer, Invitae. "The PCM platform complements current monitoring methods, and has the ability to determine a cancer therapy's effectiveness earlier than those methods for many patients, allowing clinicians

March 15, 2022 Invitae Publishes the 2022 Environmental, Social and Governance Report

Invitae (NYSE: NVTA), a leading medical genetics company, today released its 2022 Environmental, Social and Governance (ESG) Report summarizing the company's performance on key ESG criteria and highlighting its commitment to healthcare for humanity. "Continuing the progress on our ESG efforts is central to our mission and is part of our DNA," said Shelly Guyer, Chief Sustainability Officer at Invitae. "We are dedicated to transparent disclosure, collecting data to enable future goal setting, and sustainable practices to improve healthcare affordability and accessibility to all." The report provides an in-depth review of the progress made in the past year against established frameworks. It also details how Invitae continues to work toward strengthening the policies and procedures that operationalize its commitment to oversight and integration of ESG within strategy and risk management practices. The company recognizes the importance of solid governance, environmental stewardship and

February 24, 2022 Invitae Reports $460.4 Million in Annual Revenue Driven by 1.17 Million in Billable Volume in 2021

- Annual revenue grew by 65 percent and annual billable volume by 77 percent year over year -
- Full-year 2022 revenue growth guidance of 40 percent to approximately $640 million -
- Guiding to expansion of gross margin throughout 2022 and decreasing cash burn charting path to positive cash flows -
- Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time - Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and year ended December 31, 2021. "2021 was another year of industry leading growth and the addition of almost 1 million patients onto the Invitae platform, providing further evidence that the Invitae vision and one-of-a-kind testing, digital health and data network are ushering in the era of genomic health management," said Sean George, Ph.D., co-founder and CEO of Invitae. "Looking into 2022, we intend to maintain our focus on driving that shift

February 16, 2022 Invitae Launches its First CE-IVD Cancer Testing Kits In Europe

- New in-vitro diagnostic kits help patients fight cancer in the EU - Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of FusionPlex Dx ® and LiquidPlex Dx ™ in Europe, part of its industry-leading Anchored Multiplex PCR chemistry in-vitro diagnostic (IVD) products. Invitae is delivering essential high quality innovation for precision oncology in the fight against cancer. With this announcement, Invitae provides the highest quality CE-IVD products to enable European pathologists and oncologists to efficiently provide vital information, in a timely manner, to guide cancer therapy for patients. "This is a major step toward our mission to bring comprehensive genetic information into mainstream medicine," said Vishal Sikri, President of Oncology at Invitae. "Our best in class FusionPlex ® and LiquidPlex ™ tests will enable more patients access to the right cancer therapies at the right time, which is especially critical in Europe where the

February 10, 2022 Invitae to Announce Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register at the link below:
https://conferencingportals.com/event/DqFqYhVe Upon registering, each participant will be provided with call details and a conference ID. Reminders will also be sent to registered participants via email. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is

February 3, 2022 Invitae to Present at Upcoming Investor Conferences

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in virtual fireside chats at the following investor conferences: SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022, at 1:00 p.m. Eastern Time. Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 11:10am Eastern Time. A live webcast of each fireside chat may be accessed by visiting the investors section of the company website at ir.invitae.com . Replays of the webcasts will be available shortly after the conclusion of each fireside chat. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more

February 3, 2022 Invitae Supports the Biden Administration's Advancement of the Cancer Moonshot, Enhanced Recommendations on Genetic Testing for Cancer Treatment

- Recommendations include assessment of eligibility for germline genetic testing for all people diagnosed with cancer - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, applauds the Biden Administration's announcement to reignite the Cancer Moonshot with renewed White House leadership of this effort. As part of this initiative, the newly formed President's Cancer Panel also released a report on Closing the Gaps in Cancer Screening , which includes several important advancements in the use of genetic testing and access to genetic counselors for cancer patients. Cancer remains one of the leading causes of death in the United States, with an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in 2021. More than 13% of cancer patients have a clinically significant germline variant that can be revealed through genetic testing, thereby alerting the patients to their risk for second cancers as well as providing their family members with an

January 10, 2022 Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million

- 64 percent growth year-over-year in revenues
- 76 percent growth year-over-year in billable volumes
- Ended the year with more than 17,500 active healthcare provider accounts
- Active pharma and commercial partnerships expand by 68 percent
- Total patient population is more than 2.5 million with over 62 percent available for data sharing
- Presenting at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:45 a.m. Eastern/6:45 a.m. Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2021 revenue, billable volume and commercial metrics reporting approximately 64 percent growth in revenue and 76 percent growth in volume, signaling continued momentum into 2022. "We are encouraged by the acceleration of our business in 2021, particularly in light of the direct and indirect impacts on the healthcare system throughout the year," said Sean George, Ph.D., co-founder and

January 5, 2022 Invitae to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, chief executive officer, will present virtually at the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 9:45 a.m. Eastern Time. The live audio webcast of the presentation may be accessed by visiting the investors section of the company website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com . Contact: ir@invitae.com (628) 213-3369 View original content to download

Press releases

FORWARD-LOOKING STATEMENTS

Investor Contact